Radiation Oncology Department, Georges François Leclerc Cancer Center, Unicancer, Dijon, France; INSERM 1231, Cadir Team, Dijon, France.
Dosimetry Platform, Unit 1018 INSERM-CESP, Villejuif, France; Radiation Oncology Department, Gustave Roussy, Unicancer, Villejuif, France; Université Paris-Saclay, Villejuif, France.
Radiother Oncol. 2022 Jun;171:14-21. doi: 10.1016/j.radonc.2022.04.004. Epub 2022 Apr 9.
The Radiation Induced Sarcoma (RIS) is a rare but serious adverse event following radiotherapy (RT). Current RT techniques are more precise, but irradiate a larger volume at a low dose. This study aimed to describe radiation characteristics in a large series of patients suffering from RIS.
Patient-representative voxel-based anthropomorphic phantoms were used to reconstruct patient-specific RT fields for 125 patients diagnosed with RIS after primary breast cancer. For each patient, the location of the RIS onset site was determined and transferred onto the phantom as a contour. Using a treatment planning system (TPS), the dose distribution on the RIS in the phantom was calculated.
The mean dose (Dmean) received in the area where RIS subsequently developed was 47.8 ± 11.6 Gy. The median dose in the zones where RIS later developed ranged from 11 Gy to 58.8 Gy. The median time from RT to RIS development was 8 years (range 2-32 years). Analysis for predictors of time to radiation-induced sarcoma development highlighted a significant impact of age of patient during the RT whereas in multivariable analysis chemotherapy and hormonotherapy for primary breast cancer were not associated with a significant difference in time to diagnosis of RIS.
This study highlights that the dose received by the tissue in which the RIS developed was almost 47 Gy. These results are encouraging for the use of new RT techniques increasing volumes receiving low doses, without fear of an excess of RIS over the next 10 years.
放射性肉瘤(RIS)是放疗(RT)后罕见但严重的不良反应。目前的 RT 技术更精确,但以低剂量辐射更大的体积。本研究旨在描述大量 RIS 患者的放射特征。
使用患者代表性体素基于人体模型来重建 125 名原发性乳腺癌后诊断为 RIS 的患者的特定 RT 场。对于每个患者,确定 RIS 发病部位的位置,并将其作为轮廓转移到体模上。使用治疗计划系统(TPS),计算体模中 RIS 处的剂量分布。
RIS 随后发展的区域的平均剂量(Dmean)为 47.8±11.6Gy。RIS 后来发展区域的中位数剂量范围从 11Gy 到 58.8Gy。从 RT 到 RIS 发展的中位时间为 8 年(范围 2-32 年)。对 RIS 发展时间的预测因素进行分析,突出了患者在 RT 期间的年龄的显著影响,而在多变量分析中,原发性乳腺癌的化疗和激素治疗与 RIS 诊断时间的差异无显著相关性。
本研究表明,RIS 发展组织中接受的剂量几乎为 47Gy。这些结果令人鼓舞,因为新的 RT 技术可以增加低剂量接收体积,而不必担心在未来 10 年内 RIS 会增加。